Sexual Assault: A Report on Human Immunodeficiency Virus Postexposure Prophylaxis

Table 3

HIV nPEP antiviral medications doses.

(1) If the patient is ≥18 years of age with a negative urine pregnancy test, normal liver function and complete blood count tests, and a creatinine clearance of ≥50 mL/minute:
Emtricitabine/tenofovir: one tablet by mouth every day for twenty-eight days
PLUS
Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days
(2) If the patient is ≥12 and <18 years of age or is pregnant at any age with normal liver function and complete blood count tests and a creatinine clearance of ≥50 mL/minute:
Lamivudine/zidovudine: one tablet by mouth twice daily for twenty-eight days
PLUS
Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days
(3) Patients with Hepatitis B or C may be given emtricitabine/tenofovir and lopinavir/ritonivir as long as their baseline liver function tests are normal.
(4) Patients with baseline abnormal renal function should not receive emtricitabine/tenofovir. Instead, they should be started on lopinavir/ritonavir (as above) plus lamivudine/zidovudine with dosing adjustments listed below.
Dosage adjustments for patients ≥12 years of age with CrCL <50 mL/minute
CrCL	Renal dosage
30–49 mL/minute	Lamivudine 150 mg tablet QDay zidovudine 300 mg tablet BID
15–29 mL/minute	Lamivudine oral solution 100 mg/10 mL QDay zidovudine 300 mg tablet BID
5–14 mL/minute	Lamivudine oral solution 50 mg/ 5mL QDay zidovudine 300 mg tablet BID
<5 mL/minute	Lamivudine oral solution 25 mg/2.5 mL QDayzidovudine 300 mg tablet QDay

Adapted from CDC MMWR 2005 [1].